3006203
print

Autoimmune Dysautonomia Panel, Serum

AIDYS
Example Reports
Negative
Positive

Icon

Additional Technical Information

Ordering Recommendation

Use to evaluate idiopathic dysautonomia symptoms or to differentiate between autoimmune dysautonomia and the effects of chemotherapy in individuals with autonomic symptoms who are receiving cancer treatment.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube (SST)

Specimen Preparation

Separate from cells ASAP or within 2 hours of collection. Transfer three 1 mL serum aliquots to ARUP standard transport tubes. (Min: 0.5 mL/aliquot)

Storage/Transport Temperature

Frozen

Unacceptable Conditions

Amniotic fluid, ocular fluid, peritoneal fluid, synovial fluid, CSF, or plasma. Contaminated, hemolyzed, icteric, or lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 14 days; Frozen: 1 month (avoid repeated freeze/thaw cycles)

Methodology

Semi-Quantitative Cell-Based Indirect Fluorescent Antibody/Semi-Quantitative Indirect Fluorescent Antibody (IFA)/Qualitative Radioimmunoassay (RIA)/Qualitative Immunoblot

Performed

Varies

Reported

3-10 days

Reference Interval

Test Number
 Components
 Reference Interval
  CV2 Ab IgG CBA-IFA Screen, Serum Less than 1:100
  Purkinje Cell/Neuronal Nuclear IgG Scrn None Detected
  Ganglionic Acetylcholine Receptor Ab 8.4 pmol/L or less
  DPPX Ab IgG CBA-IFA Screen, Serum Less than 1:10
  CASPR2 Ab IgG CBA-IFA Screen, Serum Less than 1:10
  LGI1 Ab IgG CBA-IFA Screen, Serum Less than 1:10

Interpretive Data

Refer to report


Component Interpretation
Ganglionic Acetylcholine Receptor Antibody 0.0 - 8.4 pmol/L  Negative
8.5 - 11.6 pmol/L  Indeterminate
11.7 pmol/L or greater Positive

Compliance Category

Laboratory Developed Test (LDT)

Note

PCCA/ANNA antibody IgG is screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu) IgG by Immunoblot will be performed. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu) IgG by Immunoblot will be performed. Additional charges apply.
If CASPR2 antibody IgG is positive, then titer will be added. Additional charges apply.
If LGI1 antibody IgG is positive, then titer will be added. Additional charges apply.
If CV2 antibody IgG is positive, then titer will be added. Additional charges apply.
If DPPX antibody IgG by IFA is positive, then titer will be added. Additional charges apply.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
02/20/2024
X
X
X
X
05/15/2023
X
N/A

CPT Codes

83519; 86255 x5; if reflexed add 84182; 86256 per titer

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2007962 Purkinje Cell/Neuronal Nuclear IgG Scrn 61177-2
2009453 CASPR2 Ab IgG CBA-IFA Screen, Serum 82979-6
2009457 LGI1 Ab IgG CBA-IFA Screen, Serum 82978-8
2013959 CV2 Ab IgG CBA-IFA Screen, Serum 72504-4
3003019 Ganglionic Acetylcholine Receptor Ab 42233-7
3004361 DPPX Ab IgG CBA-IFA Screen, Serum 94676-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Alpha-3-AChR
  • Cerebellar antibodies
  • Chorea
  • Cramp-fasciculation
  • CRMP-5
  • CV2
  • Dipeptidyl aminopeptidase-like protein 6
  • Dorsal root ganglion antibody
  • DPPX
  • gAChR
  • Ganglionic acetylcholine receptor antibody
  • Gastrointestinal dysmotility
  • Hu
  • Isaacs disease
  • Motor end-plate antibody
  • Motor nerve terminal antibodies
  • Myoid antibody
  • Neuromuscular hyperexcitability
  • Neuromyotonia
  • Neuronal ganglionic acetylcholine receptor antibody
Autoimmune Dysautonomia Panel, Serum